Type 2 Diabetes | China In-Depth | China | 2019
Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as biguanides, insulin secretagogues (sulfonylureas and glinides), and alpha-glucosidase inhibitors have enjoyed high patient uptake in China due to their long market presence, physician comfort prescribing them, and favorable reimbursement. The T2D-therapy market in China will expand over the 2018-2028 forecast period, fueled by the disease’s increasing prevalence and the uptake of novel agents, particularly Johnson & Johnson’s Invokana and Sanofi’s Lyxumia. These drugs offer efficacy in lowering cardiovascular risk and eliciting weight loss, respectively, and are expected to be included in China’s NRDL. Nevertheless, despite the availability of many traditional and novel T2D agents, cost-effective therapies are still needed to improve the disease control rate, representing an opportunity for new drug developers. Additionally, with the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies are likely to be increasingly encouraged to enter the T2D-therapy market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable T2D population, and how will the drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s T2D market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the market access considerations for key therapies in the T2D pipeline in China? What sales/uptake could they secure in T2D? What are interviewed experts’ opinions of key emerging therapies?
- What are the key drivers and constraints in the Chinese T2Dtherapymarket, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary market research.
Release Date
October 2019
Geographies
China
Primary Research
Qualitative and quantitative insights based on five country-specific interviews with thought-leading endocrinologists and supported by survey data collected for this and other DRG research.
Epidemiology
Diagnosed prevalence of T2D with urban and rural breakup. Clinically relevant and market-relevant drug-treatable populations.
Forecast
Ten-year, annualized, drug-level sales and patient shares of key T2D therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging Therapies
Phase III/PR: 24 agents; Phase II: 6 agents; coverage of select early-phase products.
